The Food and Drug Administration has approved the first-ever pill for treating postpartum depression, a potentially life-threatening condition that affects hundreds of thousands of new parents across the U.S. each year.
Manufacturers Sage Therapeutics and Biogen Inc. say the drug, Zurzuvae (zuranolone), will be commercially available in the fourth quarter of this year, which could be as soon as October.
The pill — to be taken once a day for 14 days — has shown promising results in two company studies, with some patients seeing benefits after just three days.
Read this story for free
To continue reading, sign up for our newsletters and get unlimited access to WABE.org
We won't share your information with outside organizations Why am I seeing this?
